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ABSTRACT
Crohn’s disease (CD) is a chronic granulomatous inflammatory bowel disease involving
Mycobacterium avium subspecies paratuberculosis (MAP).

Other microorganisms such as

adherent-invasive Escherichia coli (AIEC) have also been proposed in CD association. To date,
only one study investigated both MAP and AIEC simultaneously using peripheral blood but not in
affected intestinal tissues. A standardized and effective antibiotic therapy against MAP and/or
AIEC is needed for better treatment. Three antibiotic drugs – Clarithromycin (CLA), Rifabutin
(RIF), and Clofazimine (CLO) have been used to treat CD patients suspected with MAP infection.
However, the outcome has been controversial. The treatment dosage is high, the duration is long,
and the reported drug side effects resulted in patient non-compliance; therefore, a lower and
effective drug dosage is needed. In this study, we developed two aims 1) to evaluate RHB 104, a
drug formula comprised of low dosages of CLA, RIF, and CLO, against clinical MAP strains invitro using fluorescence quenching method, and 2) to develop a fluorescence in-situ hybridization
method to detect both MAP and AIEC simultaneously in intestinal tissues of CD patients. A total
of 16 clinical MAP strains and 19 non-MAP strains were tested against varied concentrations of
RHB 104, CLA, RIF, and CLO. Although the MIC for all drugs ranged between 0.5-20 g/ml, the
MIC for RHB 104 was significantly lower against most MAP strains. The effect of RHB 104
against MAP was bactericidal. Unlike RHB-104 formula, CLA, CLO, and RIF dosage similar to
those in RHB-104 did not inhibit MAP growth when trialed individually and in dual-drug
combinations. The data illustrated the presence of synergistic anti-MAP activity of low dosage of
the three antibiotics in RHB-104.
We also developed a rapid and sensitive multicolor in-situ hybridization technique that
can detect MAP and AIEC using tagged-oligonucleotide probes. Non-pathogenic Escherichia coli
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(npEC) was used as a control for the study. Specifically, cultured MAP and npEC were fixed and
hybridized with MAP488 and EC647 probes, respectively. Confocal laser scanning microscope
(CLSM) revealed specific signals at 488nm for MAP and 647nm for npEC, indicating probe
binding to each bacteria. This was confirmed with hybridization of MAP with EC647 and npEC
with MAP488 resulting in absence of signals. Intestinal tissue samples from 9 CD patients were
then analyzed using our technique. Preliminary data indicated positive results in 6/6 samples for
MAP, 6/6 for npEC, 3/3 for AIEC, and 2/2 for both MAP and AIEC with MAP being more
dominant. This protocol shortened the FISH procedure from multiple days to short-hours. The
protocol allows the investigation of more than one pathogen simultaneously in the same clinical
sample. A quantitative measurement of the signals is needed.
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CHAPTER ONE: INTRODUCTION
Crohn’s Disease (CD) is a chronic inflammatory bowel disease with highly debated etiology
that includes genetic predisposition and invasion of opportunistic pathogens. Patients with active
CD generally present signs and symptoms similar to those observed in Johne’s disease, an
inflammatory bowel disease in cattle caused by Mycobacterium avium subspecies
paratuberculosis (MAP)[1]. These include abdominal pain, diarrhea usually accompanied by the
loss of blood, anemia, and weight loss[2, 3]. These clinical manifestations are commonly seen in
other inflammatory bowel diseases in humans; therefore, in order to diagnose patients with CD,
they must also present with intestinal granulomas observed during an ileocolonoscopy procedure[2].
Treatment for CD comprised immunosuppressive drugs to control the chronicity of inflammation
in affected patients but they are not completely curative[4, 5]. Antibiotic regimen has also been used
due to the isolation of opportunistic pathogens like MAP from the intestinal tissues, lymph nodes,
blood, and breast milk of CD patients[4, 6-10]. A previous case study of a CD patient with MAP
infection resulted in clinical healing and elimination of MAP infection after being administered an
antibiotic regimen comprising of Clarithromycin and Rifabutin[11]. Because of this, a cocktail of
antibiotics called RHB 104 was developed. RHB 104 comprises Clarithromycin, Rifabutin, and
Clofazimine, and it is used against moderate to severely active CD in an on-going Phase III clinical
trial. RHB 104 is comprised of lower dosages for each individual antibiotic drug than previously
administered. The first part of this thesis is to evaluate RHB 104 against MAP in-vitro to determine
its efficacy against this pathogen. Additionally, the synergistic effects of each drug at lower
dosages in RHB 104 will be evaluated in-vitro against clinical MAP strains.
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Although MAP has been associated with CD for a century, another leading pathogen under
investigation for possible etiological agent is adherent-invasive Escherichia coli. AIEC has also
been isolated from intestinal tissues, lymph nodes, and blood of CD patients[12-14]. Both MAP and
AIEC have been studied simultaneously from the peripheral blood of CD and non-CD patients[10];
however, they have not been studied together simultaneously from intestinal tissues. The second
part of this thesis is to develop a fluorescence in-situ hybridization method to detect these two
opportunistic pathogens from the intestinal tissues of patients with Crohn’s disease. This enables
visualization of these pathogens in-situ, circumventing the need for isolation and culture of MAP
and AIEC. It also determines the spatial distribution of each pathogen within and around affected
tissues. This technique enables quantification of the prevalence of MAP and AIEC in intestinal
tissues of CD patients. Lastly, it enables delineation of the potential role of MAP or AIEC as the
causative agent or opportunistic agents that exacerbate inflammation in CD.
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CHAPTER TWO: IN-VITRO EVALUATION OF RHB 104 AGAINST
CLINICAL STRAINS OF MYCOBACTERIUM AVIUM SUBSPECIES
PARATUBERCULOSIS USING FLUORESCENCE QUENCHINGMETHOD
Crohn’s disease (CD) is a chronic inflammatory bowel disease of debated etiology.
Possible causes include genetic predisposition, immune dysregulation, and environmental factors.
CD affects about 10.7 per 100,000 people-years in North America[15], and 6.3 per 100,000 peopleyears in Europe[16]. Despite the low incidence of CD in Asia[17] and Africa, recent epidemiological
studies have shown an increasing number of affected individuals in these continents[18-20]. Patients
diagnosed with CD suffer from excessive and/or nocturnal diarrhea, abdominal pain, and rapid
weight loss, all of which affect their quality of life[21]. Histologically, a cobblestoned appearance
of the mucosal layer and granulomas scattered in the intestines, particularly in the distal ileum and
colon, are observed in CD patients[22]. Similarly, these clinical and pathological manifestations
have been observed in Johne’s disease (JD), a chronic granulomatous inflammation of the
intestines in ruminants. JD is caused by an intracellular pathogen called Mycobacterium avium
subspecies paratuberculosis (MAP)[1]. Because of this and mounting evidence of the presence and
isolation of MAP from humans, MAP has been indicated as an etiological agent of CD[7, 8]. Open
and randomized clinical trials of anti-MAP therapy comprising of Clarithromycin (CLA),
Clofazimine (CLO), and Rifabutin (RIF) have shown auspicious results[11, 23, 24]. However, the drug
dosages are high and the course of therapy is long. These can pose problems such as dysbiosis of
normal gut flora and/or exacerbation of prevailing gastrointestinal (GI) symptoms such as diarrhea
and stomach pain; thus, a low, effective drug dosage is always sought after. RHB 104 is a drug
formula that is composed of all three antibiotic drugs at lower dosages than those used in previous
studies. It has been recently approved by the United States Food and Drug Administration (FDA)
3

to treat patients with moderate to severe CD in an on-going Phase III clinical trial. This study is
designed to evaluate RHB 104 in-vitro against clinical MAP strains from CD patients. Our data
suggests that the combination of lower dosages of each drug in RHB 104 has a higher efficacy of
anti-MAP activity.

Mycobacterium avium subspecies paratuberculosis
MAP is a ubiquitous, obligate pathogen that thrives in its environment such as soil,
pasteurized milk, meat products, and drinking water[25-30]. MAP is also resistant to chlorination and
pasteurization; therefore, it is not easily eliminated[31]. Since 1913, it has been suggested by Dr.
Dalziel that MAP may play a role in the pathogenesis of CD, and was further examined after its
isolation from humans by Chiodini, et al[7]. MAP is a spheroplast in humans, meaning it is cell wall
deficient[8]; as such, it cannot be identified easily by Ziehl-Neelsen acid fast staining. Furthermore,
MAP does not produce mycobactin, an iron-chelator that is essential to its growth and
replication[32]. As a result of both of these characteristics, culturing MAP from humans is extremely
difficult. However, with the improvement in culturing techniques, MAP isolates from human
samples can show positive growth in culture medium. Additionally, MAP is considered to be one
of the slowest growing mycobacteria in culture, taking between 3 to 6 months, further prolonging
detection[33]. An alternative way to detect the presence of MAP from human samples is by using
IS900 nested polymerase chain reaction (Nested PCR), which amplifies 298 base pairs of the
insertion sequence gene that has 15-18 copies in MAP DNA only[34]. Using the improved culturing
technique and Nested PCR, MAP has been isolated and identified from peripheral blood, intestinal
tissues, CD lesions, lymph nodes, and breast milk of CD patients[8, 9, 34, 35]. Regardless of this
evidence, a possible relationship between MAP and CD remains controversial because MAP is
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also present in healthy or non-CD individuals[10, 36, 37]. An effective anti-MAP therapy for CD such
as the combination in RHB 104 may provide further support to the MAP hypothesis by complete
elimination of MAP concurrent to healing in CD patients.

Treatment of Crohn’s Disease
Current treatment mainly focuses on alleviating the symptoms experienced by CD patients.
The most prominent being chronic inflammation in different parts of the GI tract that may lead to
complications such as stricture formation, ulceration, and fistulization[38-42]. CD requires medical
and surgical treatment; however, medical treatment is considered the first choice in treating and
managing it. Medical treatment

encompasses the use of anti-inflammatory drugs,

immunosuppresants, nutritional therapy, and antibiotics[38, 43-45]. If severe complications develop,
surgical treatment becomes necessary, which includes laparoscopy, strictureplasty, anastomosis,
resection, or bypass surgery[38, 39]. These surgical methods are costly and time-consuming, and they
alter patients’ lifestyles, especially when there is a recurrence of CD.
Chronic inflammation as a result of CD can be managed using anti-inflammatory drugs
such as 5-aminosalicylates (5-ASA) and steroids, or monoclonal antibodies (MAB) such as
Infliximab (Remicade) and Adalumimab (Humira)[46]. 5-ASA works in multiple ways, such as
suppressing the production of platelet activating factor[47], which is a pro-inflammatory mediator,
and decreasing the expression of interferon-[48,

49]

. Steroids work similarly to 5-ASA by

downregulating the production of pro-inflammatory mediators and cytokines. Current MAB
therapy, on the other hand, targets and blocks TNF- from mediating an inflammatory response
and recruiting immune cells to the site of infection. Both anti-inflammatory drugs and MAB
therapy have been reported to manage the symptoms experienced by CD patients, but relapse
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occurs after cessation of treatment[50-52]. These treatments are costly with insufferable adverse
effects that include but are not limited to dependency on steroids, hypersensitivity, hepatic injury,
and potential excessive immune suppression leading to re-infection[53, 54]. A more effective therapy
for CD should induce and maintain remission without any relapse, with the additional benefits of
lessening the gastrointestinal adverse effects.

Antibiotic Drugs against Crohn’s Disease
Recently, the emergence of multiple studies on the presence of pathogens in the gut of CD
patients, most notably of the presence of MAP, have led to the usage of antibiotic treatments. MAP
is closely related to the family of Mycobacterium avium complex (MAC), a pathogen infecting
HIV or immunosuppressed patients. Anti-tuberculosis drugs have not been effective against MAC;
however, other antibiotics such as Clarithromycin and Rifabutin have shown efficacy.
Clarithromycin is a macrolide antibiotic that targets the 50S ribosomal subunit and inhibits protein
synthesis[55]. Monotherapy with Clarithromycin showed effective inhibition of MAC; however,
this regimen is futile because of the possible development of antibiotic resistance[56, 57]. Another
drug or combinatory antibiotic therapy was sought after. Rifabutin, a derivative of Rifamycin, has
also been shown to effectively inhibit MAC growth[58, 59]. Rifabutin is an antibiotic drug that targets
the mycobacterial RNA polymerase, thus preventing transcription elongation[58,

60, 61]

. This

mechanism of action leads to its bactericidal property. Both Clarithromycin and Rifabutin have
been used in a combinatory regimen against MAC in HIV-AIDS patients and have shown to be
effective with lesser adverse effects[62].
The therapeutic regimen seen in MAC infection with the combinatory anti-mycobacterial
drugs was adopted because of the similarity of MAC and MAP. More importantly, these antibiotic
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drugs can also target the cellular machinery within MAP instead of targeting its cell wall, which
is lacking in MAP found in humans. Several randomized clinical trials using anti-MAP regimen
in CD patients have shown promising results[4, 63]. Gui et al in their 1997 study reported the use of
RIF and CLA[64]. In 93.5% of CD patients using the regimen (RIF-CLA), clinical remission
indicated by improvement in the Harvey-Bradshaw activity index was achieved. Initial steroid use
was also discontinued during the study. Another clinical trial using the same treatment showed
clinical improvement in 58.3% of CD patients, with complete healing of ulcers seen after >6
months of treatment[24]. A 2007 case study reported that a patient, who was suffering from
recurrence of severe CD and was being treated with anti-inflammatory drugs, attained complete
clinical remission using anti-MAP therapy[11]. These studies showed the profound effects of antiMAP therapy in CD.
Moreover, Borody et al has added Clofazimine to the anti-MAP therapy since it also targets
the transcription of DNA similar to Rifabutin[63]. Clofazimine, an antibiotic drug that is most
commonly used against leprosy, also exerts activity against mycobacteria by interacting with an
oxidoreductase in the respiratory chain to produce reactive oxygen species[65, 66]. The anti-MAP
therapy then comprised of Clarithromycin, (500-750 mg/day), Rifabutin (450 mg/day) and
Clofazimine (100 mg/day)[23]. Clinical trials have reported efficacy of this triple anti-mycobacterial
drug combination and >50% patients achieved prolonged clinical remission. Longitudinal scarring
receded to normal mucosa that further led to mucosal healing from multiple ulcerations in patients
with moderate to active CD after taking the drug combination[23, 63]. In 2007, the largest clinical
trial to date also used the triple anti-MAP therapy[4]. Selby et al reported clinical remission in 66%
of patients after 16 weeks of treatment. During the maintenance phase of the study, patients under
the antibiotic treatment showed less relapse than those of the control, providing more evidence of
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the effects of the anti-MAP regimen. Despite these reported prolonged remission and mucosal
healing, there were patients unaffected by the therapy or who experienced recurrence of CD during
therapy. Some patients in these clinical trials were also excluded because of adverse effects from
the drugs. These adverse effects include: general malaise, fatigue, headache, arthralgia, abnormal
liver enzyme levels, leukopenia, and jaundice. In addition, abdominal pain, nausea, vomiting and
diarrhea, which are common side effects from all three drugs, were also observed from the
participants of the studies. One possible cause of this is the high dosage administered to patients
for each individual antibiotic drug for a long duration of treatment lasting 12 months to more than
2 years, thus, exacerbating the GI symptoms experienced in CD. Furthermore, the long duration
of treatment of a cocktail of antibiotics taken daily can be costly and can prevent the patients from
being compliant in medicating. A single drug like RHB 104 that combines low and effective
dosages of individual anti-MAP drugs is needed.
RHB 104 is a combinatorial antibiotic drug composed of 95 mg Clarithromycin (63.3%),
10 mg Clofazimine (6.7%), and 45 mg Rifabutin (30%). Each drug concentration is lower in RHB
104 than initially used in previous clinical trials. It is undergoing Phase III clinical trials for
moderately to severely active CD in several countries. Our study is aimed to parallel the on-going
clinical trial by investigating the activity of RHB 104 in eliminating clinical MAP strains in-vitro.
In order to do this, we evaluated the activity of RHB 104 and each individual drug or two-drug
combinations at their levels in RHB 104 against clinical MAP strains.
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Materials and Methods
Mycobacterial Strains
A total of 35 Mycobacterium species were used for the drug susceptibility project (Table
1). It includes 16 clinical MAP strains, 10 Mycobacterium avium strains and 9 other
Mycobacterium species. All 16 MAP samples were obtained from the -80˚C freezer, thawed out,
and cultured in BD BactecTM MGITTM Para-TB medium (Sparks, MD) with growth supplement
and mycobactin J. Other Mycobacterium species such as M. tuberculosis, M. smegmatis, M.
intracellulari and others were also obtained from -80˚C freezer, thawed out, and cultured in BD
BactecTM MGITTM TB medium (Sparks, MD) with growth supplement. They were incubated at
37˚C. Growth was measured initially using the UV illuminator (Andromeda). The medium
contains a fluorescent molecule embedded in silicone that is oxygen sensitive, and will fluoresce
in the presence of active respiring mycobacteria. Fluorescence quenching or the absence of
fluorescence is indicative of no growth. Latter experiments were incubated at 37˚C in BD BactecTM
MGITTM 320 instrument, which measures the intensity of fluorescence, emitted and converts the
value to a measurable growth unit. A growth unit of 75 or higher is indicative of positive growth
(Figure 1).

IS900 Nested PCR
All 35 mycobacterial samples were subjected to IS900 nested PCR to confirm their MAP
identity. DNA extraction was followed per protocol as published by our group[9]. The first of two
rounds

of

PCR

used

P90/P91

primers

(5’-GTTCGGGGCCGTCGCTTAGG-3’/5’-

GAGGTCGATCGCCCACGTGA-3’) to amplify 398 bp of the IS900 gene in MAP DNA.
Subsequently, the products of the first round of PCR were used as samples for the second round.
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The

secondary

primers

were

AV1/AV2

(5’-ATGTGGTTGCTGTGTTGGATGG-3’/5’-

CCGCCGCAATCAACTCCAG-3’), amplifying 298 bp from the initial products. Amplified PCR
products were separated using agarose gel electrophoresis, and the bands were visualized using
ethidium bromide under the UV illuminator (Andromeda).

Antibiotic Drugs in Solution
Clarithromycin (CLA), Clofazimine (CLO), and Rifabutin (RIF) were kindly provided by
the manufacturer. The stock solution for Clarithromycin (1 mg/ml) was prepared using sodium
acetate in water (pH 5.0). The stock solution for Clofazimine (1 mg/ml) was prepared using
hydrochloric acid and sodium dodecyl sulfate in water. The stock solution for Rifabutin (1 mg/ml)
was prepared using absolute methanol[67].
RHB 104 was also kindly provided by the manufacturer. Due to the unavailability of the
patent-protected solvent to dissolve RHB 104, we reconstructed it by dissolving each individual
drug (CLA, CLO, RIF) in their respective solvents. Clarithromycin, Clofazimine, and Rifabutin
were combined per their percent composition (63.3% Clarithromycin, 30% Rifabutin, and 6.7%
Clofazimine) in RHB 104.

Antibiotic Drug Susceptibility Test
The minimum inhibitory concentration (MIC) was determined for each of the three
antibiotic drugs. In a BD BactecTM MGITTM Para-TB medium, 200 L of mycobacterial sample
(105 to 106 colony-forming units/ml) and 800 L of growth supplement were added. Mycobactin
J was added in MAP samples. Subsequently, each antibiotic drug was added in to each respective
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culture medium at concentrations ranging between 0.5 g/ml – 20 g/ml. Controls were
established in culture medium without any antibiotic drugs. All samples were incubated at 37˚C.

RHB 104 Susceptibility Test
The MIC of RHB 104 was also determined by inoculating mycobacterial samples with
RHB 104 per above protocol. The concentrations tested ranged between 0.5 g/ml – 20 g/ml of
RHB 104 against all mycobacterial samples. Controls were also established in culture medium
without RHB 104. All samples were incubated at 37˚C.

Determining the Synergistic Effects of the Antibiotic Drugs
To determine the synergistic effects of the three antibiotic drugs in RHB 104, 2-drug
combinations of CLA-CLO, CLA-RIF, and CLO-RIF were established (Table 2) and used against
mycobacterial samples grown in BD BactecTM MGITTM TB Medium. Growth supplement for all
samples and mycobactin J for all MAP samples were added. These were incubated at 37˚C in BD
BactecTM MGITTM 320 instrument.

RHB 104 Drug Stability Inhibitory Effect of RHB 104
Samples from the MIC/drug susceptibility experiments showing negative growth without
fluorescence under the UV illuminator as well as those reported with zero growth units were used.
Positive controls were taken from the same samples incubated without RHB 104. They were
washed twice with TE buffer at 13,200 rpm for 2 minutes. The pellets were re-suspended in 800
L of growth supplement. Each sample was added in to each respective fresh BD Bactec TM
MGITTM TB medium with 8 L mycobactin J and incubated at 37˚C.
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Results
Confirmation of MAP identity using IS900 Nested PCR
IS900 nested PCR was used on all 35 mycobacterial samples to identify MAP DNA and
confirm their identity. An agarose gel in Figure 2&3 showed bands at 398 bp for the primary PCR,
and lower bands at 298 bp for the secondary PCR for all MAP strains, and absence of bands for
all non-MAP strains. There was a total of 16/35 MAP strains, 10/35 M. avium strains, and 10 other
Mycobacterium species.

Susceptibility of Mycobacterial strains against Clarithromycin, Clofazimine,
Rifabutin, and RHB 104
The MIC for Clarithromycin, Clofazimine, Rifabutin, and RHB 104 against all 35
mycobacteria strains are given in Table 1. Initially, we utilized the fluorescence quenching method
to determine the in-vitro activity of RHB 104 and its individual antibiotic components (CLA, CLO,
and RIF) against all strains (representative samples are shown in Figure 4). The absence of
fluorescence in each culture medium indicated growth inhibition of mycobacteria. MIC was read
and reported as the concentration from the first culture medium showing absence of fluorescence.
In 81% (14/16) MAP strains that were tested, the MIC for all drugs was reported to be ≤ 1 g/ml.
In 13% (2/16) MAP strains, the reported MIC for CLA, RIF, and RHB 104 were ≤ 4-6 g/ml, but
the MIC for CLO is higher at >6 g/ml. An exception was MAP strain UCF 10, which had an MIC
of >10 g/ml in all drugs but CLA at <10 g/ml. Among non-MAP strains, the MIC for all drugs
was higher (representative samples shown in Figure 5). In 70% (7/10) of M. avium strains, the
reported MIC for CLA, RIF, and CLO were >6 g/ml, whereas the MIC for RHB 104 was ≥ 4
g/ml. M. avium strain JF1 had MIC for all drugs at >10-20 g/ml. M. avium strain NEZ was only
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tested at 1 g/ml for all drugs and it showed resistance at this level. M. avium was inhibited at <4
g/ml of CLA and RHB 104, whereas for CLO and RIF, the MIC was at >6 g/ml. Other nonMAP strains were more resistant with reported MIC for all drugs in the range of 6-20 g/ml.
The data for RHB 104 was confirmed by growth unit readings using BD BactecTM MGITTM
320 instrument. RHB 104 was tested against MAP UCF 4 and complete growth inhibition was
achieved at an MIC of 0.4 g/ml (Figure 6). In contrast, the MIC for RHB 104 against M. avium
was 3 g/ml (Figure 7). Both values correspond to what was qualitatively shown by fluorescence
quenching method (Figure 4). Overall, Clarithromycin, Clofazimine, Rifabutin, and RHB 104 had
a more potent effect at lower dosages against clinical MAP strains compared to other non-MAP
strains.

Determining the Potency of RHB 104
Although Table 1 showed similar MIC for all four drugs, the potency of RHB 104 was
determined by comparative analysis. RHB 104 at a concentration of 1 g/ml contains 633 ng/ml
of CLA, 300 ng/ml of RIF, and 67 ng/ml of CLO. The concentrations of each individual drug at
the levels of the MIC for RHB 104 against each sample were calculated (Table 1). In all samples
tested, 54% (19/35) showed resistance to CLA, RIF, and CLO at their levels in the MIC for RHB
104 for each bacteria. In clinical MAP strains, 19% (3/16) showed susceptibility to CLA but
resistance to CLO and RIF at the levels in 1 g/ml of RHB 104 (Figure 8). The remaining nonMAP samples showed resistance to CLA, RIF, and CLO at their individual levels in RHB 104
(Table 1).
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Synergistic Effects in Combined Drug Therapy
In order to further analyze the synergistic effect of CLA, RIF, and CLO in RHB 104, we
tested the activities of 2-drug combinations against MAP UCF 4 as shown in Figure 9. The drug
combination of CLA-CLO and CLA-RIF had 100% inhibition against clinical MAP strains at their
levels in 0.5 g/ml RHB 104. The combination of CLO-RIF only reached 86% inhibitory effect
against clinical MAP strains at their levels in 1 g/ml RHB 104. A comparison between the MIC
of each drug individually and in combination with one other drug is shown in Table 2. The MIC
of each individual drug against clinical MAP strains is higher than when combined with each other.

Bactericidal or Bacteriostatic Effect of RHB 104
The inhibitory effect of RHB 104 was demonstrated using fluorescence quenching method
as shown in Figure 10. A volume of MAP strain UCF 8 sample taken from culture with 1 µg/ml
of RHB 104 showed no growth by means of the absence of fluorescence after re-inoculation in to
fresh medium within 32 days. The positive control showed active growth at day 4 post-inoculation.
To confirm the bactericidal effect of RHB 104, a repeat of this experiment using MAP strain UCF
4 from culture with 1 g/ml RHB 104 was re-inoculated in to fresh medium, and incubated in the
BactecTM MGITTM 320 instrument. The result for this experiment is pending growth unit readings.

Discussion
Anti-MAP regimen, which includes Clarithromycin, Rifabutin, and Clofazimine, has been
investigated in multiple clinical trials as possible treatment for Crohn’s disease due to
Mycobacterium avium subspecies paratuberculosis being implicated as its etiological agent[4, 23, 24,
63]

. RHB 104 is a new combinatorial drug comprised of the anti-MAP regimen at lowered dosages
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than previously administered to patients. In this study, we aimed to evaluate the efficacy of RHB
104 against clinical MAP strains.
Initially, we evaluated each individual drug in RHB 104 to determine their potency against
16 clinical MAP strains and 19 non-MAP strains. Our data for the MIC of each individual drug
were comparable to previous studies that reported the MIC for Clarithromycin in the range of 0.250.5 g/ml, Clofazimine at 0.5-1 g/ml, and Rifabutin at 0.3-0.5 g/ml[68-70] against clinical MAP
strains[71]. Representative samples of non-MAP strains such as M. Smegmatis, M. intracellulari
and M. avium were susceptible at higher dosages of >4-20 g/ml of CLA, CLO, and RIF. We also
evaluated the efficacy of RHB 104 against all 35 mycobacterial samples. Unfortunately, we were
not able to dissolve RHB 104 in any diluent including those used for CLA, CLO, and RIF. In order
to replicate RHB 104, we combined each of the three drugs per their percent composition. We
obtained the MIC for RHB 104 in the range of 0.25-1 g/ml against clinical MAP strains.
Conversely, the MIC for all drugs against non-MAP strains such as M. avium, M. smegmatis, and
M. intracellulari were in the range of 4-20 g/ml, showing more resistance to RHB 104 than
clinical MAP strains. Overall, our data have shown that all three drugs and RHB 104 are more
efficacious against clinical MAP strains in contrast to non-MAP strains, reporting their MICs to
be lower.
Although the MIC for RHB 104 seems comparable to the MIC for each of the 3 individual
drugs, it has to be noted that the dosages for each drug is lower in RHB 104. In that case, a reported
MIC of 1 g/ml for RHB 104 actually contains 0.633 g/ml of CLA, 0.30 g/ml of RIF, and 0.067
g/ml of CLO. While Clarithromycin appears to be potent in bacterial inhibition at less than 633
ng/ml or 0.63 g/ml, it is futile to treat patients with one antibiotic drug for more than a year
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because of possible development of antibiotic resistance. A combination of antibiotic drugs such
as in RHB 104 can eliminate the problem with resistance while exhibiting anti-MAP activity. In
this study, we evaluated CLO and RIF individually at their levels in 1 g/ml of RHB 104 against
clinical MAP strains. Our reports showed that both drugs at lower concentrations are not effective
at bacterial inhibition by themselves. This showed that there may be some synergistic effect
between low dosages of CLA, CLO, and RIF when combined in RHB 104. We created dual
combinations of CLA-CLO, CLA-RIF, and CLO-RIF and tested them against clinical MAP strains
and other non-MAP strains. Our data showed that the dual combination of CLA-CLO and CLARIF was the most effective at completely inhibiting mycobacterial growth at their levels in 0.5
g/ml of RHB 104, particularly against clinical MAP strains. The combination of RIF and CLO
was the least effective at bacterial inhibition, even at their levels in 1 g/ml RHB 104, but still
exhibited some anti-MAP activity. This was expected as this combination contains 2 drugs with
lower concentrations in RHB 104. The combinations with CLA showed the highest anti-MAP
activity. Although CLA may be the biggest player within these combinations, again, monotherapy
with Clarithromycin may lead to antibiotic resistance. In contrast to the 2-drug combination, RHB
104 showed effective inhibition at a lower concentration of 0.25 g/ml against clinical MAP strain.
This showed that the 3 drugs are synergistic and effective at lower concentrations against MAP
than when used individually or in 2-drug combinations. It showed the superiority of RHB 104 and
its anti-MAP activity in contrast to the 3 drugs individually or in dual combination with each other.
Our data also showed the bactericidal activity of RHB 104 against clinical MAP strains.
This was exhibited when MAP harvested from a culture with RHB 104 did not grow in fresh MGIT
medium with no drugs. This can be attributed to the mechanism of action of all three drugs CLA,
CLO, and RIF that target the transcription and translation machinery within the bacteria. MAP in
16

humans lack its cell wall; therefore, using antibiotic drugs that target the cell wall will not only be
inefficient for treatment of CD, but it may also lead to complications by inhibiting some normal
flora. The combination of drugs in RHB 104 was wisely chosen as anti-MAP regimen from a wide
range of antibiotic drugs.
Our findings showed effective in-vitro activity of RHB 104 against clinical MAP strains,
as well as non-MAP strains. In parallel, if RHB 104 induces and maintains clinical remission in
CD patients from the Phase III clinical trial of RHB 104, then this will provide more evidence in
the MAP theory as a causative agent in CD.

17

Figure 1: Growth curve of Mycobacterium avium subspecies Paratuberculosis. MAP strain
UCF 4 was inoculated in a MGIT medium with OADC growth supplement and mycobactin J. It
was incubated at 37°C in BD BactecTM MGITTM 320 instrument. Growth was detected after 7
days of inoculation.
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Figure 2: Representative agarose gel of MAP strains. IS900 nested polymerase chain reaction
(IS900 Nested-PCR) goes through two rounds of PCR to confirm the identity of clinical MAP
strains 1) UCF 5 2) UCF 8 3) MAP 7 4) MAP 8B 5) MAP Ben 6) MAP Kay 7) MAP Linda 8)
MAP Para 18. The 298 bp amplicon from each clinical MAP strain is identical to the positive
control.

Figure 3: Representative agarose gel of IS900 nested-PCR products of MAP and non-MAP
strains. IS900 nested polymerase chain reaction (IS900 nested-PCR) goes through two rounds of
PCR to amplify a 298 bp segment of the IS900 gene that is specific for MAP. It was used to
confirm the identity of clinical MAP strains 1) UCF 3 2) UCF 4 3) UCF 5 4) UCF 7 5) UCF 8 8)
MAP Linda and 9) MAP Para 18. Other non-MAP strains do not have the IS900 gene in their
genome and therefore did not show any amplicons. These non-MAP strains belong to other
mycobacterial species such as Mycobacterium avium strains 6) JF 7 7) JF, 12) avium;
Mycobacterium avium intracellulari strain 10) LM1A; and 11) Mycobacterium tuberculosis.
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Figure 4: Potency of four antibiotic drugs against clinical MAP and non-MAP strains in vitro
is shown using fluorescence quenching method. Fluorescence in the tube indicates the presence
of actively respiring bacteria and an absence of fluorescence indicates bacterial growth inhibition.
Seven clinical MAP strains A) MAP Kay, B) MAP Linda, C) UCF 3, D) UCF 4, E) UCF 5, F)
UCF 7, and G) UCF 8 showed susceptibility against Clarithromycin (CLA), Clofazimine (CLO),
Rifabutin (RIF), and RHB 104 at <1 g/mL for each drug. In contrast, non-MAP strains H) M.
avium, I) M. avium intracellulari LM1A, and J) M. Smegmatis showed resistance to all four drugs
at 2 g/mL. A negative control (-) with no drug (ND) and no bacteria, and a positive control (+)
with ND and the same amount of inoculum were established.
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Figure 5: Resistant non-MAP strains were inhibited at higher concentrations of four
antibiotic drugs. Using fluorescence quenching method, the effects of Clarithromycin (CLA),
Clofazimine (CLO), Rifabutin (RIF), and RHB 104 were evaluated against non-MAP strains. A)
M. avium was inhibited by all drugs at 4 or 6 g/mL except RIF. Both B) M. avium intracellulari
LM1A and C) M. Smegmatis were still resistant to CLA, CLO, RIF at 6 g/mL. Interestingly,
RHB 104 showed potency against B) and C) compared to the individual drugs. The concentrations
of the drugs that did not inhibit bacterial growth were increased and tested up to 20 g/mL (not
shown).
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Figure 6: RHB 104 is potent at inhibiting MAP strain UCF 4 growth at low MIC levels. The
bacteria were inoculated in MGIT medium with differing levels of concentration (0.2, 0.4, 0.6,
0.8, and 1 g/mL) of RHB 104 for a period of 56 days. At 0.4 g/mL of RHB 104, MAP strain
UCF 4 was completely inhibited.
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Figure 7: RHB 104 inhibits Mycobacterium avium. The bacteria were inoculated in MGIT
medium with varying levels of concentration (1, 2 3, 4, 5, and 6 g/mL) of RHB 104 for a period
of 56 days. At a relatively high level MIC level of 3 g/mL RHB 104, Mycobacterium avium
was completely inhibited.
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Figure 8: Clarithromycin, Clofazimine, and Rifabutin in RHB 104 showed synergistic effects
against clinical MAP strains. Individually at their levels in 1 g/mL RHB 104, CLA (0.63
g/mL), CLO (0.06 g/mL), and RIF (0.3 g/mL) did not inhibit or partially inhibited growth of
clinical MAP strains A) UCF 3, B) UCF 4, C) UCF 5, D) UCF 7, and E) UCF 8. In contrast, RHB
104 completely inhibited growth, thus showing a synergistic effect between the 3 drugs even at
low dosages. A positive control with no drug (ND) was established.
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Table 1: In-vitro activity of RHB 104, Clarithromycin, Clofazimine, and Rifabutin against clinical Mycobacterium strains
MIC (g/ml)
Organism
MAP UCF 3
MAP UCF 4
MAP UCF 5
MAP UCF 7
MAP UCF 8
MAP UCF 10
MAP Strain 1
MAP Strain 3
MAP Strain 7
MAP Strain 8B
MAP Ben
MAP Kay
MAP Linda
MAP MS 137
MAP MS 185
MAP Para 18
M. avium
M. avium NEZ
M. avium JF 1
M. avium JF 2
M. avium JF 3
M. avium JF 4

CLA
<1
<1
<1
<1
<1
ND
<1
<1
<1
<1
<1
<1
<1
<4
<6
<1
<4
>1
>20
>6
>6
>6

CLO
<1
<1
<1
<1
<1
ND
<1
<1
<1
<1
>1
<1
<1
>6
<6
>1
>6
>1
>10
>6
>6
>6

RIF
<1
<1
<1
<1
<1
ND
<1
<1
<1
<1
<1
<2
<1
>6
>6
>1
>6
>1
>20
>6
>6
>6

RHB 104
<1
<1
<1
<1
<1
ND
<1
<1
<1
<1
<1
<1
<1
<4
<4
<1
<4
>1
>20
>4
>4
>4

24

Comparison Analysis
CLA (63.3%)
CLO (6.7%)
RIF (30%)
Suscep
Suscep
Suscep
g/ml
g/ml
g/ml
0.633
0.067
0.3
S
R
R
0.633
0.067
0.3
S
R
R
0.633
0.067
0.3
S
R
R
0.633
0.067
0.3
R
R
R
0.633
0.067
0.3
R
R
R
ND
ND
ND
0.633
0.067
0.3
ND
ND
ND
0.633
0.067
0.3
ND
ND
ND
0.633
0.067
0.3
ND
ND
ND
0.633
0.067
0.3
ND
ND
ND
0.633
0.067
0.3
ND
ND
ND
0.633
0.067
0.3
R
R
R
0.633
0.067
0.3
R
R
R
2.532
0.268
1.2
ND
R
R
2.532
0.268
1.2
R
R
R
0.633
0.067
0.3
ND
R
R
2.532
0.268
1.2
R
R
R
0.633
0.067
0.3
R
R
R
12.66
1.34
6
R
R
R
2.532
0.268
1.2
R
R
R
2.532
0.268
1.2
R
R
R
2.532
0.268
1.2
R
R
R

MIC (ug/ml)

Comparison Analysis
CLA (63.3%)
CLO (6.7%)
RIF (30%)
Organism
CLA CLO RIF
RHB 104
Suscep
Suscep
Suscep
g/ml
g/ml
g/ml
>6
>6
>6
<4
2.532
0.268
1.2
M. avium JF 5
R
R
R
>6
>6
>6
<4
2.532
0.268
1.2
M. avium JF 6
R
R
R
>6
>6
>6
>4
2.532
0.268
1.2
M. avium JF 7
R
R
R
>6
>6
>6
<4
2.532
0.268
1.2
M. avium JF 8
R
R
R
>6
>6
>6
<6
3.798
0.402
1.8
M. intracellulare LM1-A
R
R
R
M-Smegmatis
>6
>6
>6
<6
3.798
0.402
1.8
R
R
R
M. chelonae
>10
<10
>10
>10
6.33
0.67
3
R
R
R
M. fortuitum
>10
>10
>10
>10
6.33
0.67
3
R
R
R
M. scrofulaceum
<10
<10
<10
<10
6.33
0.67
3
ND
ND
ND
M. terrae
<10
<10
<10
<10
6.33
0.67
3
ND
ND
ND
M. tuberculosis
<10
<10
<10
<10
6.33
0.67
3
ND
ND
ND
M. xenopi
<10
<10
<10
<10
6.33
0.67
3
ND
ND
ND
M. vallae
<10
<10
<10
<10
6.33
0.67
3
ND
ND
ND
Legend: ND – not determined, R – resistance, S – susceptibility; CLA – Clarithromycin, CLO – Clofazimine, RIF – Rifabutin, MIC –
minimum inhibitory concentration
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Figure 9: Two-drug combinations showed less potency of bacterial growth inhibition than
RHB 104. A combination of CLA-CLO, CLA-RIF, and CLO-RIF at their levels in (0.25, 0.5,
0.75, and 1 g/mL) of RHB 104 were tested against clinical MAP strain UCF 4. RHB 104
showed effective bacterial growth inhibition at a low MIC level of 0.25 g/mL, whereas the 2drug combinations showed only partial inhibition.

Table 2: In-vitro activity of 2-drug combinations in RHB 104 for their synergistic effects
against MAP strain UCF 4
MIC (g/ml)
In Combination
A*
B*

Percent Inhibition
Antibiotic Drugs
(%)
CLA
0.5
100
RIF
0.5
100
CLO
0.5
100
CLA + CLO
0.32
0.03
100
CLA + RIF
0.32
0.15
100
CLO + RIF
0.07
0.3
86
Legend: *A and B are the 2 drugs in combination as written in the first column.
Individually
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Figure 10: RHB 104 showed bactericidal activity against clinical MAP strain UCF 8.
Bacteria were harvested from a previous RHB 104 drug susceptibility experiment MGIT culture.
MAP strain UCF 8 from a previous positive control with no drug was washed and A) reinoculated in a fresh MGIT medium. Another MAP strain UCF 8 from a culture with 1 g/mL of
RHB 104 that showed no fluorescence under the UV light was washed and B) re-inoculated in a
fresh MGIT medium with no drugs. After 32 days, A) positive control was fluorescent, showing
presence of actively respiring bacteria, whereas B) showed fluorescence quenching.
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CHAPTER THREE: DEVELOPMENT OF MULTICOLOR IN-SITU
HYBRIDIZATION TECHNIQUE FOR DETECTION OF PATHOGENS
FROM INTESTINAL MUCOSA OF CROHN’S DISEASE PATIENTS
Opportunistic pathogens Mycobacterium avium subspecies paratuberculosis (MAP) and
adherent invasive Escherichia coli (AIEC) have each been implicated as the causative agent in
Crohn’s Disease (CD), a chronic granulomatous inflammatory bowel disease in humans[7, 9, 72].
Although extensive studies have investigated the presence of MAP or AIEC in CD patients, only
one recent study conducted by Nazareth et al investigated the two pathogens simultaneously in
both CD and non-CD individuals[10]. Both MAP and AIEC were detected in the peripheral blood
of CD patients using polymerase chain reaction (PCR). They were both found to have higher
prevalence among CD patients as opposed to non-CD patients, leading to a possible conjoined
causation. Even so, these two pathogens have not been studied simultaneously in affected intestinal
tissues of CD patients.
MAP has long been associated with CD. In 1913, a surgeon named Thomas Dalziel first
proposed a mycobacterial causation of CD after identifying pathophysiological similarities
between Crohn’s disease (then called chronic interstitial enteritis in humans) and Johne’s disease
(JD), an inflammatory bowel disease in cattle[73]. JD is caused by MAP, a ubiquitous, acid-fast and
mycobactin-dependent bacillus. MAP was isolated from affected intestinal tissues of two CD
patients[7]; however, these isolates were found to be cell-wall deficient (CWD) and a simple ZiehlNeelsen acid fast stain yielded negative results[74]. In addition, because of its CWD-form, isolating
MAP from tissue samples and culturing it in vitro became a hurdle in identifying its presence in
CD patients. Although the development of a liquid medium containing mycobactin J enabled
culturing of MAP in vitro, MAP can still take 8 weeks to 6 months to grow. The development of
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nested PCR technique enabled identifying MAP from samples instantaneously prior to or
concurrent with culturing. Using IS900 nested PCR, a 298 base pair segment of the IS900 gene in
MAP DNA is amplified[9]; this gene is specific for MAP and has 15-18 copies in the entire genome.
With these newer techniques, further evidence has shown the presence of MAP DNA in the
mesenteric lymph nodes, breast milk, and peripheral blood of CD patients[6, 9, 10, 74-81]. The MAP
CWD form has also been found in affected tissues by in-situ hybridization[34, 82, 83].
MAP is an obligate, intracellular pathogen that evades the immune system by sequestering
itself inside phagocytic cells such as macrophages and dendritic cells[84, 85]. MAP persistence within
these cells is attributed to their ability to inhibit the fusion of phagosome and lysosome[84, 86, 87].
Phagocytic cells reside in the lamina propria of the intestines where they act as secondary defense
to invading pathogens such as MAP that penetrate the intestinal epithelial layer[88]. Similarly, AIEC
has been shown to enter epithelial intestinal tissues through a macropinocytosis-like process[89, 90].
As they traverse the epithelial cells, phagocytic cells in the lamina propria, especially macrophages,
take them up. AIEC resides in vacuoles inside the macrophages, and can also persist in the
cytoplasm[91]. The successful invasion of macrophages by AIEC is similar to that of MAP. AIEC
prevents the phagolysosome fusion and the acidification of phagosome. Their survival inside the
macrophages enables AIEC to exponentially grow within 48 hours of phagocytic cell invasion[89].
AIEC, specifically strain LF82, has been linked to CD after its isolation from the ileal
lesion of a CD patient[12, 91]. It has also been detected from the peripheral blood, intestinal mucosa,
and lymph nodes of CD patients[10, 12, 14, 92-94]. Genomic studies have shown that AIEC belongs to
the B2 phylogenetic group, which usually categorizes extraintestinal E. coli that utilizes the type
IV secretion system[95, 96]. Although AIEC has been associated with CD, several strains isolated
from patients with ulcerative colitis showed indistinguishable genetic makeup with AIEC from
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patients with CD[96]. This poses the question of causality of AIEC to CD or secondary to an
underlying causation, thus, a direct method of visualizing its presence in differing stages of CD
might provide clues as to its role in CD pathogenesis.
The advent of in-situ hybridization technique in 1969 paved way for analysis of
chromosomes and cytological components[97, 98] by visualization using radioactive materials. This
technique was further developed by using very stable fluorescent molecules for fluorescent in situ
hybridization (FISH) of RNA-DNA hybrids[99]. FISH is used in many clinical applications,
extending from diagnosing genetic diseases[100] to identifying pathogens that cannot be cultured in
vitro such as Mycobacterium leprae in lepromatous leprosy[101]. By using oligonucleotide probes,
target species such as MAP or AIEC can be identified from CD patient intestinal tissues with great
sensitivity using FISH, bypassing the limitations of culturing method and contaminations of
PCR[102]. In addition, PCR amplifies any DNA, whether it is remnant, circulating, non-infectious
DNA or DNA extracted from a viable, infectious microorganism. The misleading amplification of
DNA can lead to contradicting PCR results, as is reported in numerous studies. FISH enables
detection of DNA only from viable, infectious MAP and/or AIEC in the intestinal mucosa,
specifically pinpointing the involved pathogens at the site of inflammation. We have previously
shown using FISH that MAP is present in some CD patients[34]. Another report showed an invasive
type of Escherichia coli to be present in the ileal mucosa of CD patients using FISH but not in
healthy controls[103]. These separate, individual evidences further augmented the on-going debate
about which pathogen is the actual causative agent of Crohn’s Disease or if it is a multifactorial
causation involving multiple pathogens.
This study is aimed to develop a multicolor detection method using FISH to simultaneously
detect these two pathogens from intestinal tissue samples of CD and non-CD patients. This
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optimized method will help 1) determine the presence and prevalence of both MAP and AIEC in
affected intestinal tissues of CD patients, and 2) determine the spatial distribution of both
pathogens in affected intestinal tissues. Based on evidence from previous studies, we hypothesized
both pathogens to be present in tissue samples, with MAP being more prevalent in CD patients.

Materials and Methods
Bacterial Strains
MAP strain UCF 4 and E.coli strain K-12 (ATCC 33625) were used for development and
optimization of the protocol. Commensal, non-pathogenic EC (npEC) is expected in the gut, and
was used as a control. There was no AIEC culture obtained for this project; therefore, npEC was
used as a negative control against the AIEC probe. MAP was thawed out from -80°C freezer and
was cultured in BD BactecTM MGITTM Para-TB medium with 800 L growth supplement. In order
to prevent clustering of MAP in culture, 0.1% Tween 80 (Acros Organics, New Jersey) was added
to the culture medium. During the exponential phase, 1 mL of MAP was removed from culture
using aseptic technique. It was centrifuged at 13,200 rpm for 2 minutes, and washed in TE buffer.
The supernatant was discarded, and the pellet was re-suspended in 500 L of TE buffer. A volume
of 20 L was smeared on each glass slide, air-dried, and heat fixed. E. coli strain K-12 was also
thawed out from -80°C freezer. It was grown on a nutrient agar plate and incubated at 37°C. After
visible growth on the culture plate, one colony was removed using aseptic technique and resuspended in 500 L of TE buffer. Glass slides were smeared with 20 L of npEC. They were airdried, heat fixed, and stored until further use. Acid fast and gram stain were used to confirm the
presence on the glass slide of MAP and npEC, respectively.
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Tissue Samples
The intestinal mucosal tissue samples used in this study were obtained from tissue
collections bank in Dr. Naser’s lab. All clinical samples were received following UCF Internal
Review Board (IRB) approval. Demographic data were collected but nothing related to patient’s
contact information. Clinical samples were not collected from patients for this study; instead,
samples were collected for non-related diagnostic or therapeutic purposes. These samples
embedded in paraffin wax were taken from the -80°C. Sequential cuts of 3 m sections for each
tissue were placed on 10 glass slides. Each tissue samples was given a code to identify patient
demographics at the conclusion of this blind study (Table 4).

Preparation of oligonucleotide probes
The probes for MAP, AIEC, and npEC were adapted from previous studies with a few
modifications (Table 3)[104, 105]. The amine-modified oligonucleotides were dissolved in DNAsefree water to achieve a final concentration of 25 g/L. The oligonucleotide stock solution was
stored at -20°C for further use. The reactive dyes were dissolved in 14 L of DMSO per 250 g
and stored at -20°C until further used. A reaction mixture of 7 L of deionized water, 75 L of
labeling buffer (0.1 M sodium tetraborate buffer, pH 8.5), 4 L of a 25 g/L oligonucleotide
stock solution and 14 L of reactive dye in DMSO was added to a vial and incubated overnight at
room temperature on an oscillating shaker. After 24-hours, 10 L of 3M NaCl and 250 L of cold
absolute ethanol were added to the reaction vial and incubated at -20°C for 30 minutes. The
reaction mixture was centrifuge at 11,400 rpm (12,000 x g) for 30 minutes. The supernatant was
removed and the pellet was washed with 70% ethanol. The pellet was dried briefly, and was
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dissolved in 100 L TE buffer (stock concentration of 1 g/l). The purified oligonucleotidelabeled probe was stored at -20°C for further use.
Table 3: Oligonucleotide Probes for MAP, pathogenic E. coli, and non-pathogenic E. coli
Organis
m
MAP
AIEC

Oligonucleotide Sequence

Specificit
Probe
Fluorophore
y
IS900
MAP488
AF 488
16s rRNA AIEC546
AF 546

ATG TGG TTG CTG TGT TGG ATG G[9]
GCA AAG GTA TTA ACT TTA CTC
CC[105]
npEC
CAT GCC GCG TGT ATG AAG AA
16s rRNA
EC647
AF 647
Legend: MAP – Mycobacterium avium ss. paratuberculosis, AIEC – adherent-invasive
Escherichia coli, npEC – non-pathogenic Escherichia coli, AF – Alexa Fluor.
Bacterial Fixation

The FISH protocol was adapted from our previous study with some changes[34]. Briefly,
bacteria were fixed with 4% paraformaldehyde for 30 minutes at room temperature (RT). After
fixation, they were washed three times in 1X PBS (pH 6.8) for 10 minutes each. The bacterial
membranes were permeabilized in 100 L of 1% SDS and 20 g/mL of Proteinase K at 55°C for
30 minutes. The enzyme was inactivated using 0.2% glycine for 3 minutes at RT. Bacterial slides
were washed as stated above. They were dehydrated with 50%, 80%, and 100% ethanol washes
for 1 minute each. Bacterial slides were washed in xylene for 1 minute to remove excess lipids
before going through another round of 100%, 80%, and 50% ethanol washes for 1 minute each.
Lastly, they were incubated in 1X PBS (pH 6.8) for 1 hour at RT.

Bacterial Fluorescent In-situ Hybridization
For each bacterial slide, a mixture containing 20 L of hybridization solution (1% Triton
X100, 2X SSC, 500 g/ml denatured sperm DNA, 10% dextran sulfate, 50% deionized formamide
and water) with 100 ng oligonucleotide probe was boiled for 10 minutes and displaced on ice for
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another 10 minutes. Prior to hybridization, bacterial slides were incubated in a pre-hybridization
buffer (2X SSC, 20% dextran sulfate, 50% formamide, and water) for 5 minutes at 50°C. The
bacterial slides were transferred in a hybridization chamber. The hybridization mixture was added
on to the slides for an overnight incubation at 37°C. After 24-hours, the slides were washed on a
shaker for 15 minutes each with 2X SSC (RT), 1X SSC (RT), 0.3X SSC (40°C), and 0.3X SSC
(RT). Slides were further washed with diH2O three times for 10 minutes each at RT, and allowed
to air dry in the dark. Slides were mounted with anti-photobleaching medium (Vector Laboratories,
Burlingame, CA).

Fluorescent In-situ Hybridization on Intestinal Tissue Samples of CD Patients
The tissues were de-paraffinized in three washes of xylene each for 10 minutes. They were
then washed for 10 minutes each in 100%, 80%, and 50% ethanol. The tissues were incubated in
1X PBS (pH 6.8) for 5 minutes and air-dried. A cocktail solution of 20 L hybridization buffer
and 1 L oligonucleotide probe per slide were mixed and added on to the dried tissue slides. The
slides were covered in parafilm and transferred in to hybridization chambers. They were incubated
at 55°C for 90 minutes. After hybridization, the slides were washed for 15 minutes in 2X SSC
(RT), 1X SSC (RT), 0.3X SSC (40°C), and 0.3X SSC (RT). The three final washes for the slides
were in diH2O at RT for 10 minutes each. The slides were air-dried in a dark room. One drop of
mounting medium with DAPI (Vector Laboratories, Inc. Burlingame, CA) was spotted on the
tissue. The slide was covered with a cover slip and sealed with clear nail polish.
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Analysis
The cultured bacterial slides and tissues slides were analyzed using confocal scanning laser
microscopy (CSLM). The signals were detected through each respective channel at wavelengths
of 488 nm, 546 nm, and 647 nm. The images for each bacterial slides were taken at a total
magnification of 1000-1500x and the images for tissue slides were taken at a total magnification
of 630-945x. The signals detected were analyzed together using ImageJ 1.49v (National Institutes
of Health, USA).

Results
Specificity of each oligonucleotide probe
The sequences for MAP, AIEC, and npEC were analyzed using BLAST. The antisense
strands were determined as shown in Table 3. The non-pathogenic EC probe sequence has a 100%
identity (E-value: 5e-04) with the 16s rRNA of EC strain K-12 (Figure 11). The MAP probe
sequence has a 100% identity (E-value: 8e-06) with the IS900 sequence of MAP (Figure 11). Lastly,
the AIEC probe sequence has a 100% identity (E-value: 7e-07) with the 16s ribosomal RNA
(rRNA) of AIEC strain LF82 (Figure 11). In addition, the AIEC probe sequence is also showing
specificity against npEC strain (E-value: 1e-05).

FISHing for cultured MAP and npEC
Suspensions of cultured MAP and npEC were each smeared on separate glass slides and
were targeted using the specific probes MAP488 and EC647, respectively. Under CSLM analysis,
the emission signal at 647 nm (red) was detected from the npEC slides (Figure 12), and at 488 nm
(green) from the MAP slides (Figure 13). The specificity of the probes to each respective bacterial
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target was also tested. EC647 probe was used against cultured MAP and MAP488 probe was used
against cultured npEC. There were no signals detected under the CSLM from neither cultured
npEC nor cultured MAP, showing probe specificity (image not shown).

FISHing for AIEC
There was no cultured AIEC acquired for this project. The probe specificity for AIEC
(AIEC546) was tested against the cultured EC strain K-12, thus serving as the negative control.
Under CSLM analysis, no signals were detected at 546 nm wavelength (Figure 14), confirming
that the probe is specific only to AIEC and not to commensal Escherichia coli.

FISHing for MAP, AIEC, and npEC on Intestinal Mucosa
A total of 9 tissue samples from the intestinal mucosa of CD patients were used for the
experiments (Table 4). In 6 tissue samples (Figure 15), red signals (647 nm) were detected under
the CSLM, indicating the presence of npEC in the intestinal mucosa of CD patients. In 6 other
tissue samples (Figure 16), green signals (488 nm) were detected under the CSLM, indicating the
presence of MAP in the lamina propria of the intestines. AIEC was also detected sparingly in 3
other tissue samples (Figure 17) from CD patients. In 2/9 tissue samples, all three bacteria were
detected individually using each oligonucleotide probe. These probes individually were able to
target the respective bacteria npEC, MAP, and AIEC, showing the localization of each bacterium
within the lamina propria of the intestinal tissues of CD patients.
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Dual-FISH on tissue samples
Following the aforementioned results, a cocktail of two oligonucleotide probes were
mixed: (i) MAP and npEC probes (Figure 18), (ii) MAP and AIEC probes (image not shown), and
(iii) npEC and AIEC probes (image not shown). The dual probe cocktails were used to target each
respective bacterium in the intestinal tissue samples of CD patients. In Figure 18, the use of both
MAP and npEC oligonucleotide probes showed the presence of both bacteria in the intestinal
mucosa. This simultaneous detection enabled identification of the spatial distribution of each
bacterium in the intestinal mucosa. In some areas, there was an overlap of signals, which could be
from co-localization of these bacteria.

Discussion
A bacterial etiology of Crohn’s Disease has been extensively studied after the isolation of
opportunistic pathogens MAP or AIEC from CD patients. However, a causative agent of CD has
not been established due to conflicting results[106-110]. A previous study has detected both
intracellular pathogens simultaneously from the peripheral blood of CD patients but these
pathogens have not been detected from affected intestinal tissues[10]. The aim of this study was to
develop a multicolor imaging technique using fluorescent in-situ hybridization to detect MAP and
AIEC simultaneously in order to determine the presence and spatial distribution of MAP and AIEC
from the intestinal mucosa of CD patients. This study presented an optimized technique using
FISH to (i) detect cultured MAP and npEC in vitro and (ii) detect MAP, AIEC, and npEC in situ
from the intestinal mucosa of CD patients.
Initially, we have optimized a protocol that enables detection of MAP and npEC from
culture using oligonucleotide probes and FISH. In this study, npEC was used as a negative control
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against AIEC and it was also used to show that npEC is present in human intestinal tissue samples
as expected. The labeled oligonucleotide probes were shown to bind to their targeted bacteria,
MAP or npEC. The specificity of the oligonucleotide probes was further tested by using MAP
probe against npEC, and npEC probe against MAP. The absence of signals showed that the
oligonucleotide probes only bind to their respective bacterial target. Although AIEC was not
cultured and used in this experiment, the specificity of labeled oligonucleotide probe, which
sequence was adapted from a previous study[105], was used against npEC. The absence of the signal
from npEC showed that the oligonucleotide probe only binds to AIEC. This is beneficial in
delineating the difference between npEC and adherent invasive EC. As a result, we developed a
protocol for FISH using oligonucleotide probes and optimized it using cultured bacteria to
simultaneously detect MAP and npEC.
Further optimization of the protocol was needed to work with intestinal mucosa of CD
patients. Initially, the probes were used individually to detect MAP, AIEC, or npEC from tissue
samples. All of the tissue samples tested showed the presence of npEC as expected. Both MAP
and AIEC were also detected individually from the intestinal tissue samples of CD patients,
specifically in the lamina propria. MAP was detected in its almost spherical form, as we have
shown previously[9]. These results led to combination of probes in a cocktail solution to achieve
the goal of the study, a multicolor detection method. Using the optimized protocol, simultaneous
detection of MAP and EC, MAP and AIEC, or AIEC and EC from the tissue samples were
achieved. An overlay of the images showed that there might be co-localization of some of these
bacteria in the lamina propria of the intestinal mucosal samples. It was not surprising to see a
possible co-localization of these bacteria in the lamina propria of the intestines because of the
resident macrophages that phagocytize invading microorganisms.

38

Although the optimized protocol detected the presence of MAP, npEC, and AIEC both
from culture and in intestinal tissue samples, there were a few limitations to this study. Positive
controls for the AIEC oligonucleotide probe must be establish to determine its specificity and
sensitivity in targeting only AIEC while discriminating against npEC. Additionally, further studies
can be done to confirm the detected signals for MAP, npEC, and AIEC using labeled antibodies
specific for each bacterium. An important addition to this validation is to identify phagocytic cells
within the lamina propria to determine the actual spatial distribution of each bacterium.
Overall, a protocol using fluorescent in situ hybridization method was developed and
optimized to target MAP, npEC, and AIEC from cultured microorganisms as well as tissue samples
from CD patients. This method can be applied to a larger sample size to determine the presence
and role of MAP and AIEC in different stages of Crohn’s Disease. Additionally, other pathogens
such as Listeria monocytogenes, Klebsiella pneumonia, and Clostridium difficile have also been
associated with Crohn’s Disease. This FISH protocol can be applied for a multiple detection of all
these pathogens to determine which of them is the causative agent of CD. It may also be interesting
to find out whether CD is a chronic disease that is caused by one pathogen such as MAP or AIEC,
or it is caused by multiple pathogens.
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Table 4: Intestinal Tissue samples from Crohn's Disease patients.
Patient #

Age

Sex

Ethnicity

Family Hx of IBD

Site of Tissue
npEC MAP AIEC
Sample
NLF-1745
30
F
C
N/A
CD
N/A
X
NLF-1036
23
M
Unknown
N/A
CD
N/A
NLF-1637
31
F
Unknown
N/A
CD
N/A
NLF-2800
51
M
Unknown
N/A
CD
N/A
X
NLF-2963
28
F
C
Brother: CD
CD
N/A
NLF-3115
34
M
C
N/A
CD
Right colon
NLF-3127
38
F
C
N/A
CD
Transverse colon
X
NLF-0014
31
M
C
N/A
CD
N/A
NLF-1040
26
F
AA
N/A
CD
N/A
X
NLF-1130
48
F
C
N/A
CD
Rectum
X
X
NLF-0145
27
F
AA
N/A
CD
N/A
X
X
X
NLF-1624
49
M
H
N/A
CD
N/A
NLF-1703
31
F
AA
Father: IBD
CD
N/A
NLF-1780
22
F
H
N/A
CD
N/A
X
NLF-2313
50
M
H
N/A
CD
N/A
NLF-2446
50
M
AA
N/A
CD
N/A
NLF-0268
63
F
Unknown
N/A
CD
Ascending colon
X
X
X
NLF-0597
31
F
C
N/A
CD
Ileum
X
X
NLF-0656
63
F
H
N/A
CD
N/A
Legend: F – female, M – male, C – Caucasian, AA – African American, H – Hispanic, N/A – not applicable, CD – Crohn’s
Disease, IBD – inflammatory bowel disease
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Diagnosis

Figure 11: BLAST analysis of the oligonucleotide probes for non-pathogenic EC, MAP, and AIEC. The 16s rRNA sequence for
the non-pathogenic E.coli probe was analyzed against b) MAP (green) and c) AIEC (yellow) genome, whereby showing the probe is
specific for non-pathogenic E. coli. The IS900 sequence for the MAP probe was also analyzed against a) non-pathogenic EC (red) and
c) AIEC (yellow). The low e-value of the MAP probe against MAP was indicative of a more biologically related significance than that
with non-pathogenic EC and AIEC, thus conferring specificity. Lastly, the AIEC probe was analyzed against a) non-pathogenic EC and
b) MAP. In this instance, the probe showed biological relation with both non-pathogenic EC and AIEC, with the latter showing more
specificity.
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Figure 12: FISHing for non-pathogenic E. coli using EC647. Cultured E. coli grown
on a nutrient agar plate was smeared and heat-fixed on a glass slide. This was used to
optimize the fluorescent in situ hybridization (FISH) technique using the non-pathogenic
E. coli probe EC647 to target the 16s rRNA of the non-pathogenic E. coli. The left panel
a) was the differential interference contrast (DIC) image, showing bacterial structure. The
right panel c) captured the red signal emitted from the EC647 probe bound to the target.
The middle panel b) showed an overlay of both aforementioned images. Total
magnification at 1500x. Scale bar at 10 m.

Figure 13: FISHing for Mycobacterium avium paratuberculosis using MAP488
probe. Cultured MAP was used to optimize the FISH technique using the MAP488 probe
that targets the IS900 sequence in the MAP DNA. The left panel a) showed the structural
image of the bacteria, which is b) overlaid (middle panel) with the fluorescent green
signal from the right panel c). The signals correspond to the structure, showing adherence
to the target by the MAP488 probe. Total magnification at 1000x. Scale bar at 10 m.
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Figure 14: FISHing for non-pathogenic E. coli using the pathogenic probe AIEC546.
Cultured non-pathogenic E. coli was used as a negative control to test the specificity of
the pathogenic probe AIEC546. The DIC image on the left panel a) showed the presence
of bacteria on the slide; however, c) no signal was emitted by the AIEC546 probe. This
showed b) probable non-binding of the probe to the non-pathogenic E. coli. Total
magnification at 1000x. Scale bar at 10 m.
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Figure 15: Non-pathogenic E.coli is present in the intestinal mucosa of Crohn’s disease patients. In six different tissue samples
from CD patients, the EC647 oligonucleotide probe was used to FISH for non-pathogenic (commensal) E. coli. The red signals (647
nm) in A-F were detected in the lamina propria for each tissue sample (M-R). The background tissue was stained with DAPI (G-L).
Scale bar at 10 m.
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Figure 16: Mycobacterium avium paratuberculosis penetrated the lamina propria of intestinal tissues of CD patients. The
MAP488 oligonucleotide probe was used in FISH to target MAP in the intestinal tissues of 6 CD patients. The signals (A-F) emitted
at 488 nm were overlaid with the surrounding DAPI-stained tissues (G-L) showing localization of MAP within the lamina propria (MR). Scale bar at 10 m.
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Figure 17: FISHing for adherent invasive E. coli in the intestinal tissues of CD
patients. Using the AIEC546 oligonucleotide probe, AIEC was targeted as shown by the
yellow signals emitted at 546 nm (A-C). Background tissues were stained with DAPI (DF). AIEC, like MAP and npEC, were also localized in the lamina propria of the intestinal
tissues of 3 CD patients (G-I). Scale bar at 10 m.
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Figure 18: Dual FISHing of intestinal tissues shows bacterial presence and co-localization. In tissue samples obtained from CD
patients, two oligonucleotide probes EC647 and MAP488 were used simultaneously to FISH for non-pathogenic EC (A&E), and
MAP (B&F). The background tissue sample stained with DAPI (C&G) overlaid with the two signals (D&H) showed the presence of
both bacteria in the lamina propria of the intestinal tissues. In some areas, there may also be co-localization of the npEC and MAP.
Scale bar at 10 m.
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CHAPTER FOUR: CONCLUSION
A possible microbial causation in Crohn’s Disease has long been investigated due to the
individual isolation and detection of opportunistic pathogens such as Mycobacterium avium
subspecies paratuberculosis and adherent-invasive Escherichia coli[10]. This correlation has
brought about treatment options using antibiotic therapy. In this study, we determined and
established the efficacy in vitro of a new combinatorial antibiotic drug RHB 104 against clinical
MAP and non-MAP strains. In doing so, we also showed a synergism between the lowered dosages
of the three drugs in RHB 104. Secondly, we detected both MAP and AIEC from the intestinal
mucosa of CD patients using the multicolor fluorescent in situ hybridization technique that we
developed as a part of the study.
We consider MAP to be a leading etiological agent for CD after isolation and detection from
affected intestinal tissues, lymph nodes, peripheral blood, and breast milk of CD patients[7, 9, 10, 83].
This correlation has shaped treatment options on antibiotic drugs, specifically Clarithromycin,
Rifabutin, and Clofazimine. This combination was used in previous studies resulting in varying
results, possibly attributed to the high drug dosages administered over a long period of treatment[4].
In contrast, a patient who suffered severe recurring CD, and who have utilized all source of
treatment from surgical to pharmacological successful treatment was successfully cured with no
relapse after treatment with this drug combination[11]. In RHB 104, the dosages of these three drugs
were lowered. Our findings confirmed that despite the low dosages in RHB 104, it is still
efficacious against clinical MAP and non-MAP strains. This finding is more important in that,
RHB 104 is more potent against clinical MAP strains as shown by the lower MIC for RHB 104
than in their counterpart non-MAP strains. A more suggestive role of RHB 104 in treating MAP
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infection is the synergism between low dosages of the three drugs Clarithromycin, Rifabutin, and
Clofazimine in RHB 104. When RHB 104 was compared to each individual drug at low dosages
or in dual combinations, we found that RHB 104 is superior in its inhibitory effects against clinical
MAP strains. Although RHB 104 is effective against clinical MAP strains in vitro, there is still
another leading pathogen, AIEC to consider.
The second part of our study was to investigate both MAP and AIEC simultaneously from
affected tissues. After countless optimizations and experimentation, we developed a multicolor
visualizing method to detect these two pathogens using cultured bacteria. This method using
fluorescent in situ hybridization was utilized to detect these pathogens from intestinal mucosa of
CD patients. We detected both of these pathogens within the lamina propria of the intestinal
mucosa with a higher prevalence and greater presence of MAP in CD patients. This may suggest
a collusion of both opportunistic pathogens in the pathogenesis of CD as opposed to a solitary
agent. However, we should not dismiss the idea of having a primary agent and a secondary agent
precipitating the chronic inflammation seen in CD. Further studies need to be done in order to
determine the actual role of MAP and AIEC in the pathogenesis of CD.
Although our findings did not establish the causality of MAP and/or AIEC in Crohn’s disease,
they provided a means of simultaneous investigation of these pathogens in situ to advance our
understanding of their role in this recurring disease. Our findings also suggested that RHB 104 is
a combinatorial antibiotic drug that is efficacious against clinical MAP strains, especially for CD
patients with MAP infection.
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